IPM Take
Pharmaceutical companies have solved one politically powerful problem: GLP-1 treatment no longer has to begin with a needle.
They have not solved the access crisis.
Oral semaglutide and orforglipron are turning obesity treatment into a contest between tablets, injections and increasingly complex multi-receptor medicines. Manufacturing scale is expanding, but coverage remains fragmented and most eligible patients worldwide are still unlikely to receive treatment.
A pill may change the patient experience.
Only policy can determine who gets one.
Executive Summary
The oral obesity market expanded sharply between late 2025 and mid-2026. Oral Wegovy, containing semaglutide, was approved in the United States in 2025 and launched in early 2026. In July 2026, the European Commission approved the Wegovy pill as the first oral GLP-1 medicine for weight management in the European Union.
Eli Lilly’s Foundayo, or orforglipron, was approved by the FDA in April 2026. Unlike semaglutide, it is a non-peptide small molecule and can be taken without restrictions relating to meals or water. Oral semaglutide must be taken in the morning on an empty stomach, followed by a wait of at least 30 minutes before food, drinks or other oral medicines.
The commercial report that prompted this article argues that oral products, manufacturing capacity and cardiometabolic outcomes are becoming the defining competitive issues in the incretin market. That broad direction is credible, but its market-size projections come from a commercial press release rather than an independently reviewed analysis and should be treated cautiously.
WHO has warned that formulation innovation alone will not deliver equitable access. Even with rapid production expansion, GLP-1 therapies are projected to reach fewer than 10% of people who could benefit by 2030. WHO has called for measures including pooled procurement, tiered pricing and voluntary licensing.
Why it matters
- Patients: Tablets may reduce needle anxiety and create additional treatment choices, but daily dosing and administration requirements may suit some patients better than others.
- Policymakers: Oral formulations do not remove the need for national eligibility criteria, sustainable financing and long-term obesity-care pathways.
- Payers and HTA bodies: Reimbursement should consider cardiovascular and metabolic outcomes, adherence and total healthcare value, not weight loss alone.
- Clinicians: A pill is not automatically simpler. Treatment selection should consider effectiveness, adverse effects, dosing requirements, comorbidities and patient preference.
- Industry: Manufacturing capacity is becoming as strategically important as drug development, but expanding supply without improving affordability will leave the central access problem intact.
The GLP-1 revolution arrived with an injection pen.
Its next phase is arriving in a tablet.
Oral semaglutide has been used for type 2 diabetes for several years, so oral GLP-1 treatment itself is not new. What changed in 2026 is that oral therapy became a genuine competitive force in obesity care.
Novo Nordisk launched the Wegovy pill in the United States after approval in late 2025. In July 2026, the European Commission approved it as the first oral GLP-1 treatment for weight management in the European Union. Eli Lilly’s Foundayo, orforglipron, received US approval in April.
The market is no longer simply asking which medicine produces the greatest weight loss.
It is asking which company can manufacture enough treatment, place it on formularies and persuade patients to remain on it for years.
A pill removes one barrier, not every barrier
Many patients prefer tablets to injections. Oral treatment could make prescribing easier in primary care and reduce resistance among people who are uncomfortable using injection devices.
But “oral” is not a single patient experience.
The Wegovy pill must be taken in the morning on an empty stomach with a limited amount of water. Patients must wait at least 30 minutes before eating, drinking or taking other oral medicines. Foundayo can be taken without those food and water restrictions.
For one patient, a daily pill may feel simpler than a weekly injection.
For another, remembering a tablet every morning before breakfast and other medicines may be more difficult.
That is where genuine personalised care begins. Not with marketing one route as universally preferable, but with matching treatment to a person’s routine, comorbidities, preferences and likely adherence.
Manufacturing is now part of clinical access
The companies are preparing for a market measured not only in prescriptions, but in production capacity.
Novo Nordisk announced a DKK 3 billion investment to expand oral GLP-1 manufacturing in Ireland. Lilly has committed billions of dollars to new US facilities expected to produce orforglipron and other synthetic or peptide medicines.
This matters because previous GLP-1 demand repeatedly collided with limited supply.
Oral products could reduce reliance on injection pens, fill-finish capacity and some distribution infrastructure. Small-molecule drugs such as orforglipron may also offer different production possibilities from peptide therapies.
But oral manufacturing is not effortless, and additional factories do not guarantee equitable distribution.
Companies will naturally prioritise markets that can pay.
Global need does not determine commercial allocation. Purchasing power does.
Access remains the harder innovation
WHO’s warning is blunt: even with production expanding rapidly, GLP-1 therapies may reach fewer than one in ten people who could benefit by 2030.
That gap will not be closed by changing the route of administration.
It will be determined by price, insurance coverage, health technology assessment, prescribing restrictions and whether health systems treat obesity as a chronic disease requiring continuing care.
An affordable injection is more accessible than an unaffordable pill.
A tablet placed behind multiple prior-authorisation barriers is not a primary-care revolution.
A medicine that patients can begin but cannot afford to continue may deliver temporary weight loss without durable population benefit.
Oral competition could place downward pressure on prices. It could also produce a new premium market in which convenience itself becomes commercially priced.
Policymakers should not wait to find out which version emerges.
Outcomes must replace the weight-loss arms race
The incretin market is expanding beyond glucose control and body weight. Companies are pursuing indications involving cardiovascular disease, kidney disease, liver disease and sleep apnoea, while developing dual and triple agonists intended to act through several biological pathways.
This broader cardiometabolic ambition is welcome.
It also raises the evidentiary standard.
Payers should increasingly ask whether a treatment prevents heart attacks, delays diabetes, protects kidney function, reduces hospitalisation and improves quality of life. Percentage weight loss is important, but it cannot remain the only currency of value.
WHO’s obesity guideline similarly frames GLP-1 medicines as one component of lifelong, person-centred care, not a replacement for prevention, healthier environments and functioning health systems.
The oral GLP-1 era is real.
But the central political question has barely changed.
The pharmaceutical industry is learning how to put powerful obesity treatment into a pill.
Health systems still have to decide whether that pill will be a public-health intervention or a product available mainly to those who can pay.
